Metraipolis › archive › dc_bc0f0f76a61d

Real-World Evidence of the Efficacy and Safety of Second-Line Therapy After Gemcitabine and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer — Europe PMC PMID:40940917

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40940917
DOI
10.3390/cancers17172821
License (as archived)
solo-consultazione
Archived
2026-11-10T06:50:32.808Z
SHA-256 of the archived text
119991a465f048acab285efd191f5e8896c3b374abd477e88fc5f7aeb4af88b5
Stable URL of this page
https://metraipolis.com/documento/dc_bc0f0f76a61d

How to cite

Real-World Evidence of the Efficacy and Safety of Second-Line Therapy After Gemcitabine and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer — Europe PMC PMID:40940917 — Europe PMC (en), https://europepmc.org/article/MED/40940917 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bc0f0f76a61d (Metraipolis archive dc_bc0f0f76a61d, sha256 119991a465f048acab285efd191f5e8896c3b374abd477e88fc5f7aeb4af88b5)
BibTeX
@misc{dcbc0f0f76a61d,
  title = {Real-World Evidence of the Efficacy and Safety of Second-Line Therapy After Gemcitabine and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer — Europe PMC PMID:40940917},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40940917},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bc0f0f76a61d; sha256 119991a465f048acab285efd191f5e8896c3b374abd477e88fc5f7aeb4af88b5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40940917. Agents can read the archived copy with the MCP tool read_document.